Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025

Trevi Therapeutics, Inc.

Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).
The trial is evaluating Haduvio for the treatment of refractory chronic cough.
Topline data from the RIVER trial is expected to be reported in the first quarter of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.